Founded in 1992, Alzheimer’s Research UK is the UK’s leading dementia research charity. Their work is dedicated to furthering our understanding of the causes, diagnosis, prevention, treatment and cure of diseases such as Alzheimer’s. Characterised by declines in memory and other cognitive functions such as thinking and reasoning, these progressively worsening neurodegenerative and ultimately fatal diseases sadly remain without a cure. In this exclusive interview, we speak with Ian Wilson, Deputy Chief Executive, to hear about the vital work conducted by Alzheimer’s Research UK.

To begin, please tell us how Alzheimer’s Research UK came to fruition.

Alzheimer’s Research UK was founded in 1992 as the Alzheimer’s Research Trust, with the mission to defeat dementia through research. Cambridge-based Dr Sarah-Jane Richards and Barbara Langlois, along with Joe Pollock and Dr Martin Weale spearheaded early work in establishing the charity and bringing in our original trustees and scientists.

Shocked by the lack of investment in dementia research, this small team of pioneers originally set out to fund the building of a dedicated research centre in Cambridge, a city known as a centre of research excellence. However, their focus soon shifted to funding scientists in universities instead to ensure that as much money as possible went directly into research.

What are the main aims and objectives of Alzheimer’s Research UK?

Our vision is a world where people are free from the fear, harm and heartbreak of dementia. Without effective treatments, one in three children born today will die with dementia. Today, there are no dementia survivors but our wholehearted belief is that research can and will change this.

Backed by our passionate scientists and supporters, we’re challenging the way people think about dementia, uniting the big thinkers in the field and funding the innovative science that will deliver a cure.

How does Alzheimer’s Research UK support research? What types of research do you focus on?

Dementia is caused by physical diseases that attack the brain and we fund a broad range of research projects to understand dementia and drive us towards better diagnosis, preventions and treatments.

We work with academics to fund the very best ideas; we also sit at the intersection between academic brilliance and the pharmaceutical industry, to ensure that potential new treatments are taken forward as quickly and as safely as possible, and of course, we are working to ensure we can detect and diagnose the diseases that cause dementia as early as possible.

Alzheimer’s Research UK has invested in just under 1,000 projects across all forms of dementia since 1998. Our supporters have allowed us to fund thousands of dementia researchers based in 75 organisations across the UK and 31 international institutions.

From people to pipettes and from Aberdeen to Exeter, our funding is making a huge difference.

What are Alzheimer’s Research UK’s most significant achievements to date?

Our research investment is increasing rapidly and we have invested more than £136 million in groundbreaking research since 1998. Our research has identified new avenues of biology that urgently need exploring.

One of the key hallmarks of Alzheimer’s disease is the build-up of amyloid in the brain. Scientists think that these abnormal protein clumps start a damaging chain reaction that gets in the way of how our brain cells work. Removing amyloid from the brain is a key target for drug development. Our scientists took the time to learn from the first trial of a treatment designed to clear amyloid protein from the brain. They saw the potential for it to guide future clinical trials. Their findings are helping researchers make smarter decisions about how new treatments are being developed today.

Of course, our charitable remit goes further, and we also hold governments to account to ensure as much funding as possible is made available for dementia research. Through our campaigning work and thanks to our amazing supporters who backed our campaign, the government recently pledged to double dementia research funding to £1.6bn over the next 10 years, which now needs to be delivered.

How is the general public involved in your work?

Dementia is one of the world’s greatest challenges. It shatters lives and leaves millions heartbroken. In all, we’ve funded £136 million of research projects. This is only possible because of the generosity of our supporters.

Thousands of people across the country, and even more across the world, are helping us in so many ways by raising money and awareness, giving up their time to volunteer and sharing their personal stories with the media. We are always looking for new supporters to help us in our work!

2020 was, of course, a challenging year for everyone. What specific difficulties has the COVID-19 pandemic created for Alzheimer’s Research UK and how are these being overcome?

The need for investment in dementia research has never been more urgent. COVID-19 is threatening dementia research efforts, with many projects delayed and some studies cut completely, and a lack of future funding opportunities forcing many scientists to consider leaving dementia research. Losing these scientists would mean not only a loss of resource to continue vital studies, but a loss of valuable expertise that has taken years to build up.

The pandemic is also having a catastrophic impact on people with dementia. Figures show that a quarter of people who have died in the first wave with COVID-19 in England, Wales, and Scotland, also had dementia. For the sake of people with dementia and their families, we must protect progress in research.

Alzheimer’s Research UK is obviously facing a predicted drop in income as a result of COVID-19, affecting our ability to fund new research this year. Yet dementia research has been making huge strides, and life-changing treatments are in our sights. Alzheimer’s Research UK and our scientists have pivoted to delivering events online and conducting research in a socially distanced manner as far as possible.

The charity has also had strong financial processes in place and we are delighted to see income still continue to arrive into the charity. Even in the darkest times, it has been wonderful to see, where possible, our fundraising activity and income continue, and it really highlights to me what incredibly loyal supporters we have.

During this period one of our Board wrote to me and said ‘Crises are a test of the values and deep characteristics of an organisation, and also of the quality and characteristics of its people. It is no surprise that Alzheimer’s Research UK is scoring so highly on both!’. I think this sums things up nicely.

Finally, looking now to the future, what are the long-term goals for Alzheimer’s Research UK?

One of the challenges we face is that the diseases cause dementia start decades before the symptoms show. Therefore, to have the best chance of halting them, we need to intervene decades earlier, when these diseases first start to take hold. To do this we will utilise new technologies and breakthroughs in data science and machine learning to produce a revolutionary way of detecting and ultimately diagnosing the diseases that cause dementia.

The aim is to collect huge amounts of digital data generously donated by research study volunteers using smartphone apps and wearable devices, like watches and headbands. By linking data to clinical tests, such as brain scans, we’ll identify digital data patterns, or ‘fingerprints’, which allow us to detect the earliest signs of diseases like Alzheimer’s.

If we do this, we have the best chance of stopping these diseases before the symptoms of dementia start to get in the way of life, keeping people connected to their world, their families and themselves for longer.

W: https://www.alzheimersresearchuk.org/

Twitter: @AlzResearchUK

Reference
https://doi.org/10.33548/SCIENTIA631

Want to republish our articles?

 

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.


More articles you may like

Dr Benjamin Bradley | Cause, Consequence, and Natural Selection: A New Vision of Darwin’s Psychological Work

Dr Benjamin Bradley | Cause, Consequence, and Natural Selection: A New Vision of Darwin’s Psychological Work

The theory of evolution by natural selection stands at the heart of modern biology. But what exactly is the causal status of natural selection in evolution? Dr Benjamin Bradley from Charles Sturt University in Australia is challenging long-held assumptions, arguing that Darwin himself saw natural selection as a consequence of other processes, not a cause of evolution in its own right. This crucial distinction opens up new perspectives on how evolution relates to psychology and behaviour.

Dr David Nairn | Time-Interleaved Analogue-to-Digital Converters: Breaking Speed Barriers in Digital Signal Processing

Dr David Nairn | Time-Interleaved Analogue-to-Digital Converters: Breaking Speed Barriers in Digital Signal Processing

In our increasingly digital world, the ability to convert analogue signals into digital data quickly and accurately is crucial for everything from mobile phones to medical devices. Dr David Nairn from the University of Waterloo, Ontario, has been at the forefront of developing and improving time-interleaved analogue-to-digital converter technology to enable faster and more efficient digital signal processing. His work is helping to overcome key challenges in high-speed digital systems, paving the way for more advanced electronic devices.

Dr. Petr Kelbich | Investigating Inflammatory Conditions in Extravascular Body Fluids: An Important New Parameter

Dr. Petr Kelbich | Investigating Inflammatory Conditions in Extravascular Body Fluids: An Important New Parameter

Diagnosing disorders of the brain and other organs can often feel like solving a challenging puzzle. Analyzing non-blood body fluids provides valuable clues that can help address this complexity. To enhance this process, Dr. Petr Kelbich from Jan Evangelista Purkyně University and Masaryk Hospital in Ústí nad Labem, Czech Republic, introduced an innovative method called Cytological-Energy Analysis.

Dr Michelle Pantoya | More Bang for Your Buck: How Changing the Chemical Properties of Aluminum Particles Increases their Power

Dr Michelle Pantoya | More Bang for Your Buck: How Changing the Chemical Properties of Aluminum Particles Increases their Power

Aluminum particles are widely used in various energy generating applications, such as fuels. However, due to their high reactivity with atmospheric oxygen, they must be coated in a chemical ‘shell’ in order to prevent spontaneous combustion. This highly protective shell obstructs oxygen from reaching the aluminum core, limiting aluminum’s potential to produce power. Dr Michelle Pantoya from Texas Tech University has led a research team to explore alternative shell compositions. New shell chemistry has exciting implications for aluminum use in rocket fuels and other propellants.